2012
DOI: 10.1021/mp300311b
|View full text |Cite
|
Sign up to set email alerts
|

Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
87
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 65 publications
(93 citation statements)
references
References 48 publications
6
87
0
Order By: Relevance
“…The chemoresistant counterpart (HT29-dx cells) line was generated by culturing parental cells in the presence of increasing concentrations of doxorubicin for 20 passages [41]. HT29-dx cells have higher Pgp, MRP1 and BCRP than HT29 cells [68]; moreover, compared to HT29 cells, HT29-dx cells have a higher IC50 for doxorubicin (25.51 ± 1.33 μM versus 2.74 ± 0.67 μM; p < 0.01), irinotecan (0.91 ± 0.18 μM versus 0.05 ± 0.01 μM; p < 0.001), oxaliplatin (98.75 ± 6.08 μM versus 4.75 ± 0.71 μM; p < 0.001), and 5-fluorouracil (8.35 ± 0.64 μM versus 1.06 ± 0.14 μM; p < 0.05), representing a reliable model of MDR cells. For the present work, HT29-dx cells were grown in medium containing 200 nM doxorubicin.…”
Section: Methodsmentioning
confidence: 99%
“…The chemoresistant counterpart (HT29-dx cells) line was generated by culturing parental cells in the presence of increasing concentrations of doxorubicin for 20 passages [41]. HT29-dx cells have higher Pgp, MRP1 and BCRP than HT29 cells [68]; moreover, compared to HT29 cells, HT29-dx cells have a higher IC50 for doxorubicin (25.51 ± 1.33 μM versus 2.74 ± 0.67 μM; p < 0.01), irinotecan (0.91 ± 0.18 μM versus 0.05 ± 0.01 μM; p < 0.001), oxaliplatin (98.75 ± 6.08 μM versus 4.75 ± 0.71 μM; p < 0.001), and 5-fluorouracil (8.35 ± 0.64 μM versus 1.06 ± 0.14 μM; p < 0.05), representing a reliable model of MDR cells. For the present work, HT29-dx cells were grown in medium containing 200 nM doxorubicin.…”
Section: Methodsmentioning
confidence: 99%
“…These were used at 20 µM in 0.25 mL of caspase assay buffer (25 mmol/L Hepes, 0.1% w/v CHAPS, 10% w/v sucrose, 10 mmol/L DTT, 0.01% w/v egg albumin, pH 7.5). The reaction was stopped by adding 0.1% w/v ice-cold trichloroacetic acid (0.75 mL) and the fluorescence of AMC fragment released by active caspases was then read (Fluoroskan Ascent fluorimeter, ThermoLabsystems, Helsinki, Finland) at 380 nm and 460 nm (excitation and emission wavelengths, respectively) [66].…”
Section: Caspase Activitymentioning
confidence: 99%
“…{Fulda, 2010 #29}(ref) While the therapeutic potential of harnessing the mitochondrial disruptive effects of Dox has been contemplated for over a decade (18), only recently have specific molecular targeting strategies been employed to deliver Dox to mitochondria. Such strategies include liposome encapsulation (19), chemical conjugation of mitochondrial targeting moieties (20,21) chemical modification (22), and nanoparticle encapsulation (23), all of which have demonstrated the capacity to induce cell death in cancer cells, validating this therapeutic strategy. Particularly promising is the ability of these targeted compounds to overcome clinically relevant resistance mechanisms that exist outside of mitochondria.…”
Section: Introductionmentioning
confidence: 99%
“…Particularly promising is the ability of these targeted compounds to overcome clinically relevant resistance mechanisms that exist outside of mitochondria. (20)(21)(22) Previous work has demonstrated that mitochondria-targeted Dox (mtDox, see Figure 1A for structure) is able to inhibit TopoII activity in vitro, leading to the induction of apoptotic cell death in cancer cells, while evading resistance mechanisms such as the upregulation of Pgp efflux pumps in the cellular membrane. (20) This phenomenon has been observed for a number of targeted anticancer agents and is likely the result of direct mitochondrial sequestration.…”
Section: Introductionmentioning
confidence: 99%